181 related articles for article (PubMed ID: 24623282)
1. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.
Ally MS; Tang JY; Joseph T; Thompson B; Lindgren J; Raphael MA; Ulerio G; Chanana AM; Mackay-Wiggan JM; Bickers DR; Epstein EH
JAMA Dermatol; 2014 May; 150(5):542-5. PubMed ID: 24623282
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
[TBL] [Abstract][Full Text] [Related]
5. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
Yang X; Dinehart SM
JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
[No Abstract] [Full Text] [Related]
6. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series.
Wong C; Poblete-Lopez C; Vidimos A
J Am Acad Dermatol; 2020 Jun; 82(6):1539-1542. PubMed ID: 32092372
[No Abstract] [Full Text] [Related]
7. Fibroblasts regulate variable aggressiveness of syndromic keratocystic and non-syndromic odontogenic tumors.
Hong YY; Yu FY; Qu JF; Chen F; Li TJ
J Dent Res; 2014 Sep; 93(9):904-10. PubMed ID: 24972872
[TBL] [Abstract][Full Text] [Related]
8. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
Dréno B; Kunstfeld R; Hauschild A; Fosko S; Zloty D; Labeille B; Grob JJ; Puig S; Gilberg F; Bergström D; Page DR; Rogers G; Schadendorf D
Lancet Oncol; 2017 Mar; 18(3):404-412. PubMed ID: 28188086
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of keratocystic odontogenic tumor cell lines derived from sporadic and basal cell nevus syndrome patients.
Noguchi K; Wakai K; Kiyono T; Kawabe M; Yoshikawa K; Hashimoto-Tamaoki T; Kishimoto H; Nakano Y
Int J Oncol; 2017 Dec; 51(6):1731-1738. PubMed ID: 29039452
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
[TBL] [Abstract][Full Text] [Related]
11. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
12. Non-syndromic and syndromic keratocystic odontogenic tumors: systematic review and meta-analysis of recurrences.
Antonoglou GN; Sándor GK; Koidou VP; Papageorgiou SN
J Craniomaxillofac Surg; 2014 Oct; 42(7):e364-71. PubMed ID: 24815763
[TBL] [Abstract][Full Text] [Related]
13. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449.
Goldberg LH; Landau JM; Moody MN; Kazakevich N; Holzer AM; Myers A
Arch Dermatol; 2011 Jul; 147(7):839-41. PubMed ID: 21422324
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of TLR3 and TLR4 in keratocystic odontogenic tumor (KCOT): A comparative immunohistochemical study in primary, recurrent, and nevoid basal cell carcinoma syndrome (NBCCS)--associated lesions.
Leonardi R; Perrotta RE; Crimi S; Matthews JB; Barbato E; dos Santos JN; Rusu M; Bufo P; Bucci P; Pannone G
J Craniomaxillofac Surg; 2015 Jul; 43(6):733-7. PubMed ID: 25976039
[TBL] [Abstract][Full Text] [Related]
15. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
16. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Wolfe CM; Green WH; Cognetta AB; Hatfield HK
Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
[No Abstract] [Full Text] [Related]
17. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
18. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.
Booms P; Harth M; Sader R; Ghanaati S
Ann Maxillofac Surg; 2015; 5(1):14-9. PubMed ID: 26389028
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
